Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

NCT00784303 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Cancer

Interventions

DRUG: Lenvatinib (DTC Cohort)
DRUG: Lenvatinib (MTC Cohort)

Sponsor

Eisai Inc.